IMS Foresees Generics Market Surging Ahead
This article was originally published in PharmAsia News
Executive Summary
Pharmaceutical research firm IMS expects the 2008 global pharmaceutical and health care industry to grow at 5 percent to 6 percent, a rate slightly less than the 6 percent to 7 percent of 2007. Drugs enjoying some $20 billion worth of sales will lose their patent this year, making space for generics to proliferate at 14 percent to 15 percent to reach over $70 billion, thanks to rising demand worldwide. Generics-producing countries such as China, Brazil, Mexico, South Korea, India, Turkey and Russia are set to expand their market at 12 percent to 13 percent to hit a total of $90 billlion in 2008. China, growing at 16 percent, ranks ninth on the global pharmaceutical market. IMS predicts that domestic demand will propel the country to sixth position in 2011. (Click here for more - Chinese Language)
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.